A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Published:2019 Issue:3 Volume:34 Page:247
ISSN:2093-596X
Container-title:Endocrinology and Metabolism
language:en
Short-container-title:Endocrinol Metab

Author:

Sargeant Jack Alistair¹²^ORCID,Henson Joseph¹²^ORCID,King James Adam²³,Yates Thomas¹²,Khunti Kamlesh¹⁴,Davies Melanie Jane¹²^ORCID

Affiliation:

1. Diabetes Research Centre, University of Leicester, Leicester, UK.

2. NIHR Leicester Biomedical Research Centre, University Hospital of Leicester NHS Trust and the University of Leicester, Leicester, UK.

3. National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, UK.

4. NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRC), Leicester, UK.

Funder

National Institute for Health Research

Publisher

Korean Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.3803/EnM.2019.34.3.247

Reference79 articles.

1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

3. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

4. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

2. The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study;Diabetes Therapy;2024-09-09

3. Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss;Diabetes & Metabolism;2024-09

4. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs;Obesity Pillars;2024-09

5. Second Generation Anti-Obesity Medications;Current Pediatrics Reports;2024-08-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3